Kirkland-Led AbbVie To Pay $8.7B For Cerevel Therapeutics
Kirkland & Ellis LLP-advised AbbVie Inc. said Wednesday it has agreed to buy Latham & Watkins LLP-guided Cerevel Therapeutics and its neuroscience treatment portfolio for approximately $8.7 billion....To view the full article, register now.
Already a subscriber? Click here to view full article